The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Open accessAbstract
R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here that R-2HG also exerts a broad anti-leukemic activity in vitro and in vivo by inhibiting leukemia cell proliferation/viability and by promoting cell-cycle arrest and apoptosis. Mechanistically, R-2HG inhibits fat mass and obesity-associated protein (FTO) activity, thereby increasing global N 6-methyladenosine (m 6 A) RNA modification in R-2HG-sensitive leukemia cells, which in turn decreases the stability of MYC/CEBPA transcripts, leading to the suppression of relevant pathways. Ectopically expressed mutant IDH1 and S-2HG recapitulate the effects of R-2HG. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. Collectively, while R-2HG accumulated in IDH1/2 mutant cancers contributes to cancer initiation, our work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m 6 A/MYC/CEBPA signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of these, up to 90% of diffuse intrinsic pontine gliomas (DIPG) harbour a point mutation in canonical ( HIST1H3B (H3.1)) or variant ( H3F3A (H3.3)) histone H3, resulting in a lysine 27 to methionine (K27M) substitution 101-103 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · cited 1×
“To address this question, we conducted integrative analysis of the TCGA AML microarray dataset (Ley et al., 2013) with our RNA-seq data shown in Figure 2A.”
MethodN6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558 · cited 3×
“Knockdown of YTHDF2, a major m6A reader that is responsible for the decay of m6A-modified mRNA transcripts (Wang et al., 2014b) and that is known to bind MYC mRNA (Figure S4N), noticeably increased the stability and expression of MYC transcripts in leukemia cells (Figures 4J and S4O).”
BackgroundResultSelf-citationGenomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 7×
“80% of grade II-III gliomas and secondary glioblastoma (GBM), 10%–20% of acute myeloid leukemia (AML) patients, and at a lower rate in other cancers; most of these lesions involve mutations of arginine (R) residues in codon 132 for IDH1 (IDH1R132) and residues 140 and 172 for IDH2 (IDH2R140 and IDH2R172) (Brat et al.,…”
BackgroundInfluentialCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO
Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.-G., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.687 · Cited by 4,106
Self-citationA METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z., Deng, X., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1432 · Cited by 3,433
Self-citationComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,888 · cited 2×
“Primary AML cells with IDH mutations are also sensitive to JQ1, an inhibitor of MYC signaling (Delmore et al., 2011), often with an IC50 lower than 1 mM, thoughwith a higher IC50 than AML cells with wild-type IDH (Figure 7B; Table S4), likely due to the hyper-activation of MYC signaling in the former.”
BackgroundSelf-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 3×
“Because IDH mutants block cell differentiation and promote tumor transformation, and inhibition of mutant IDH (IDHi) can reverse this effect, R-2HG (as the major metabolic product of IDH mutants) has been regarded as an oncometabolite (Figueroa et al., 2010; Lu et al., 2012; Rohle et al., 2013;Wang et al., 2013; Xu et…”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Nicholson, L. S., Guimarães-Teixeira, C., Liu, J., Chien, R., Xu, J., Poh, H. X., Pan, Y.-X., & Jaffrey, S. (2025) · bioRxiv · doi:10.1101/2025.10.22.681652 · Cited by 5
Targeting of Post-Transcriptional Regulation as Treatment Strategy in Acute Leukemia
Podszywalow‐Bartnicka, P., Wołczyk, M., & Piwocka, K. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94421 · Cited by 2
MiR-150-5p inhibits cell proliferation and metastasis by targeting FTO in osteosarcoma
Xu, L., Zhang, P., Zhang, G., Shen, Z., & Bai, X. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.047704 · Cited by 2
“Consequently, this process facilitates the proliferation and differentiation of these cells [27,28].”
BackgroundZhao, M., Fu, W., Zhang, Y., Ma, J., Yang, X., Nie, H., Wu, W., Gao, F., Wu, F., Xin, M., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143228 · Cited by 2
Xie, Y., Tian, W., Zheng, C., & Li, M. (2025) · Advanced Functional Materials · doi:10.1002/adfm.70661 · Cited by 2
Tan, Y., Zhou, C., Bian, S., Bian, H., Ren, Y., Walter, W., Pang, J., Cheng, T., Wang, H., Yang, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08045-6 · Cited by 2
Rewriting the RNA code: an m6a-centric framework to classify tumors and guide combination therapies
Sun, Y., Wu, J., Chen, G.-H., Ma, H., Li, W., Tan, H., & Yang, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1749911 · Cited by 4
Li, X., Liu, M., Cao, W., Wu, Q., Lu, L., Han, Q., Guo, J., & Chen, M. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c07298 · Cited by 2
Emerging functions of m6A-modified circRNAs and their targeting strategies in lung cancer
Wang, H., Yuan, Y., Li, C., Jiang, X., & Wang, J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1794138 · Cited by 2
“…(e.g., METTL3/14) or activating “erasers” (e.g., FTO/ALKBH5) can alter the expression and function of tumor-associated circRNAs, thereby suppressing tumor growth or reversing drug resistance (Yi et al., 2025; Yankova et al., 2021; Guirguis et al., 2023; Chen et al., 2012; Su et al., 2018).”
Self-citationZhu, Y., Ma, K., Hao, Q., Fu, K., Hei, F., Ning, S., Yin, Z., Guo, W., Zou, H., & Tan, Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02667-w · Cited by 2
RNA methylation in cell death: mechanisms and clinical applications
Shang, S., Wang, X., Xu, X., Huang, Y., Tang, D., Wang, J., & Ma, L. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02706-6 · Cited by 2
Izadpanah, R., Izadpanah, A., & Alt, E. U. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108304 · Cited by 2
A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC
Kuganesan, N., Pan, M., Jiang, H., Melemenidis, S., Ye, J., Richter, S. A., Diehn, M., Casey, K. M., Graves, E. E., Le, Q., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed6463 · Cited by 2
Metabolic regulation in urological tumors: Interplay with epigenetics and epitranscriptomics
Miranda‐Gonçalves, V., Guimarães‐Teixeira, C., Henrique, R., & Jerónimo, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85652-2.00019-1 · Cited by 2
The Distribution and Significance of IDH Mutations in Gliomas
Tran, N. T. N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.97380 · Cited by 2
Yi, J., Liu, R., Liu, Y., Guo, T., Li, Y., & Zhou, Y. (2022) · Genes · doi:10.3390/genes13112011 · Cited by 2
Li, P., Xiong, P., Li, X., Zhang, X., Chen, X., Zhang, W., Jia, B., & Lai, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26851 · Cited by 2
Targeting the IDH1R132H mutation in gliomas by CRISPR/Cas precision base editing
Weber, R., Vasella, F., Klimko, A., Silginer, M., Lamfers, M. L. M., Neidert, M. C., Regli, L., Schwank, G., & Weller, M. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae182 · Cited by 2
“19 In the clinic, the mutant IDH1 inhibitor ivosidenib conferred prolonged disease control in patients with progressive or recurrent IDH-mutant gliomas, although limited to tumors lacking contrast enhancement.”
Xie, L., Fan, N., Ding, X., Zhang, T., Wang, W., Ji, P., & Wu, H. (2024) · Gene · doi:10.1016/j.gene.2024.149094 · Cited by 2
RNA methylation: where to from here for hematologic malignancies?
Guirguis, A. A. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104694 · Cited by 2
FTO Alleviates Hepatic Ischemia‐Reperfusion Injury by Regulating Apoptosis and Autophagy
Wang, P., Zhu, L., Xiang, M., Zhang, R., Zheng, X., Zheng, Z., & Li, K. (2025) · Gastroenterology Research and Practice · doi:10.1155/grp/5587859 · Cited by 2
Yang, Y., Ni, W.-J., Yang, Y., Liao, J., Yang, Y., Li, J., Zhu, X.-Z., Guo, C., Xie, F., & Leng, X.-M. (2025) · Medical Oncology · doi:10.1007/s12032-024-02597-x · Cited by 2
FTO deficiency facilitates epithelia dysfunction in oral lichen planus
Fan, Y., Hao, Y., Ding, Y., Wang, X., & Ge, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102463 · Cited by 2
The m6A reader YTHDF1 facilitates nasopharyngeal carcinoma proliferation and migration via c-MYC
Han, P., Xiao, Z., Xia, T., Wu, T., Li, S., Ye, Y., Zeng, H., Zeng, M., Zhong, Q., & Huang, X. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110833 · Cited by 2
“…regulation of c-MYC, a master oncogene that governs glycolysis, cell cycle progression, and drug resistance (30, 31). c-MYC mRNA m6A modifications are functionally divergent: the 5 ′ end sites of c-MYC RNA mainly promote mRNA degradation, whereas the 3 ′ end sites enhance mRNA stability (32, 33).”
Self-citationCancer research driven by cutting-edge multi-disciplinary technologies
Lyu, Q., Feng, Y., Shi, R., Wu, J., & Han, W. (2020) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2020-0638 · Cited by 2
Targeting epigenetic alterations in the treatment of glioma
Okechukwu, C. E. (2021) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_3_21 · Cited by 2
Functions of MicroRNA Methylations in Cancer: From Bench to Bedside
Duforestel, M., Courant, F., Paré, L., Sérandour, A. A., & Cartron, P. (2021) · RNA technologies · doi:10.1007/978-3-030-71612-7_20 · Cited by 2
Regulation of RNA methylation by therapy treatment, promotes tumor survivalPreprint
Bukhari, S. I. A., Truesdell, S. S., Datta, C., Choudhury, P., Wu, K. Q., Shrestha, J., Maharjan, R., Plotsker, E., Elased, R. K., Laisa, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.19.540602 · Cited by 2
“…over time by eIF2α phosphorylation, can promote PHGDH, which enhances αKG (Li et al., 2021; Pacold et al., 2016) that activates m6A demethylases (Kim and Lee, 2021; Su et al., 2018); this would then downregulate m6A on METTL3 mRNA and thus METTL3 translation at later times of therapy treatment.”
BackgroundSavino, A. M., & Stuani, L. (2024) · Haematologica · doi:10.3324/haematol.2023.284893 · Cited by 2
“Low levels of FTO and hyperactivation of MYC signaling were observed in IDH mutant AMLs and D-2HG resistant cells, and led to the maintenance of glycolysis and OxPHOS following D-2HG 7 .”
BackgroundThe m6A-circRNA axis: a therapeutic prospect for gastric cancer
Li, Z., Gu, Y., Gu, H., She, Q., & Tong, Y. (2026) · Cell Biology and Toxicology · doi:10.1007/s10565-026-10184-1 · Cited by 2
A Wnt twist in FTO’s role in cancer progression
Navickas, A., & Goodarzi, H. (2021) · Nature Cancer · doi:10.1038/s43018-021-00224-6 · Cited by 1
Targeting FTO by Dac51 contributes to attenuating DSS-induced colitis
Peng, C., Zheng, C., Zhou, F., Xie, Y., Wang, L., Chen, D., & Zhang, X. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109789 · Cited by 1
Emerging Roles of Epigenetic Regulators in Maintaining Hematopoietic Stem Cell Homeostasis
Wang, H., Han, Y., & Qian, P. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_3 · Cited by 2
Variable calling of m6A and associated features in databases: a guide for end-users
Song, R., Sutton, G. J., Li, F., Liu, Q., & Wong, J. J. L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae434 · Cited by 1
“…preprocessing pipelines of databases,we compared database peak coordinates derived from two public accessions: NOMO-1 m6A-seq from Su et al. 2018 [63] (GSE87190, with input in GSM2324291, and immunoprecipitation in GSM2324292); and H1299 meRIP-seq from Lin et al. 2016 [64] (GSE76367, with input…”
MethodResultMohammadi, Z., Jazi, M. S., Jafari, S. M., Mir, S. M., Asadi, J., & Amanlou, M. (2025) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_9_25 · Cited by 1
“The previous studies suggest that the suppression of FTO may lead to an increase in m6A content within RNA (16, 17, 59).”
Passive shaping of intra- and intercellular m6A dynamics via mRNA metabolism
Dierks, D., Shachar, R., Nir, R., García-Campos, M. A., Uzonyi, A., Wiener, D., Toth, U., Rossmanith, W., Lasman, L., Slobodin, B., et al. (2025) · eLife · doi:10.7554/elife.100448.3 · Cited by 1
Şahin, N. Ö., Bayyurt, B., Arslan, S., & Bakır, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10931-3 · Cited by 1
“Previous studies have associated FTO overexpression with oncogenesis [28 , 29 ].”
Zhang, X., Wang, Z., Xie, X., Liu, G., Dong, Z., & Yang, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01738 · Cited by 1
Yang, Y., Nie, Y., Wu, R., Han, R., Zhao, Y., Yang, R., Yuan, Y., Gao, X., Chen, H., Zhang, F. L., et al. (2025) · Antioxidants and Redox Signaling · doi:10.1177/15230864251394709 · Cited by 1
“IDH mutation reduces the proliferation of neural stem cells and glioma cells, and the onco-metabolite D-2HG derived from mutant IDH is recently reported to sensitize HT1080 cancer cells to ferroptosis inducers (Su et al., 2018; Wang et al., 2019).”
Self-citationRNA epigenetic modification for immune cell reprogramming and therapeutic translation
Zhang, Y., Liu, A., & Li, H.-B. (2026) · Fundamental Research · doi:10.1016/j.fmre.2025.12.028 · Cited by 1
Impact of FTO Genetic Variants on Colorectal Cancer Risk: A Case–Control Study
Yan, Z., Zhou, X., Wu, W., Xu, H., Zhang, Z., & Zhang, X. (2026) · DNA and Cell Biology · doi:10.1177/10445498251413504 · Cited by 1
“FTO in fl uenced cancer development and progression through various mechanisms in a range of malignancies, such as acute myeloid leukemia (Su et al., 2018), lung cancer (Ding et al., 2020), esophageal cancer (Liu et al., 2020), and breast cancer (Niu et al., 2019).”
Li, C., Jiang, X., Yuan, Y., Chen, X., Pu, S., Lian, K., Li, L., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1694842 · Cited by 1
Self-citationMetabolic oxidoreductases: central regulators of the epigenetic landscapes in stemness
Lee, H., Roe, J., & Youn, H. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01687-2 · Cited by 2
“Pharmacological inhibition of FTO has shown promise in restraining cancer stem cells and could potentially push them toward differentiation or death 135 .”
Qu, L., Li, J., Ding, S., Long, Q., & Yi, W. (2026) · The International Journal of Biological Markers · doi:10.1177/03936155261443650 · Cited by 1
The Role of N 6 ‐Methyladenosine Modification in Health and Disease
Li, L., 孙元海, Zheng, W., Li, L., Feng, Y., Qi, M.-Y., & Li, H. (2026) · MedComm · doi:10.1002/mco2.70767 · Cited by 1
“However, the inherently low levels of FTO in R-2HG-resistant cells render R-2HG incapable of exerting its anticancer effects [ 332 ], suggesting that chronic R-2HG treatment may induce tumor cell desensitization.”
Wen, Q., Liu, C., Li, C., & Yuan, X. (2026) · Gene · doi:10.1016/j.gene.2026.150260 · Cited by 1
Self-citationXi, C., Pang, J., Oliaeimotlagh, M., Mao, R., Zhi, W., Jones, K., Hu, T., Shi, H., Ande, S., Horuzsko, A., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09052-x · Cited by 1
Mitochondrial Energy Metabolism in Cancer, Immunoregulation and Antitumour Response
Patrício, J. S., Mendes, C., & Gameiro, P. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_17 · Cited by 1
RNA‐Binding Proteins: Function, Biological Mechanisms, and Therapeutic Opportunities
Li, L., Yan, X., Ji, Q., & Zhang, H. (2026) · MedComm · doi:10.1002/mco2.70938 · Cited by 1
“R ‑2 ‑hydroxyglutarate (R ‑2HG), although classically linked to IDH ‑mutant tumors, can also exert antileukemic effects in IDH ‑wildtype settings by inhibiting methyltransferase-like 3 (METTL3), increasing global m6A levels, and destabilizing oncogenic transcripts such as MYC [ 141, 142 ].”
How Epitranscriptomic Machinery Senses Environmental Cues
Jalali, S., & Ahi, E. P. (2026) · Advanced Biology · doi:10.1002/adbi.70154 · Cited by 1
Cross-talk and clinical value of m[superscript 6]A regulatory gene in bladder cancer
Zhou, B., Luo, Q. F., & Ye, Z. (2021) · BMC Urology · doi:10.1186/s12894-021-00880-x · Cited by 1
Effect of demethyltransferase FTO on tumor progression
SHENG, L., Shen, Y., & Yang, H. (2022) · Biocell · doi:10.32604/biocell.2022.021032 · Cited by 1
Akinlalu, A., Njoku, P. C., Nzekwe, C. V., Oni, R. O., Fojude, T., Faniyi, A. J., & Olagunju, A. S. (2022) · Scientific African · doi:10.1016/j.sciaf.2022.e01347 · Cited by 1
Wu, Y., Xiao, Y., Tian, L., He, B., Liu, J., Li, Z., Yang, H., Chen, Y., Luo, Q., Li, B., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02630-9 · Cited by 1
Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients
Leventoğlu, E., Şahin, G., Yeşil, Ş., Bozkurt, C., Yüksek, N., Fettah, A., Toprak, Ş., Bilgin, B. K., Çapkınoğlu, E., EROGLU, N., et al. (2023) · Medeniyet Medical Journal · doi:10.4274/mmj.galenos.2023.48768 · Cited by 1
Modification patterns and metabolic characteristics of m6A regulators in digestive tract tumors
He, B., Hu, Y., Chen, H., Xie, X., Gong, C., Li, Z., Chen, Y., Xiao, Y., & Yang, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24235 · Cited by 1
“M6A modification is the most prevalent posttranscriptional modification in mRNA of eukaryotic organisms, and the biological regulation of this modification is now widely understood and well-studied [6 – 8].”
BackgroundDowdy, T., & Larion, M. (2026) · Methods · doi:10.1016/j.ymeth.2026.08.005 · Cited by 1
Pavić, A. K., Čonkaš, J., Mumlek, I., Zubčić, V., & Ozretić, P. (2024) · Life · doi:10.3390/life14101230 · Cited by 1
RNA modifications in the regulation of hematopoiesis and leukemogenesis
Liu, F., & Wang, L. (2020) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0129 · Cited by 1
A peptide-centric local stability assay to unveil protein targets of diverse ligandsPreprint
Li, K., Chen, S., Wang, K., Wang, Y., Fang, Z., Lyu, J., Zhu, H., Li, Y., Yu, T., Yang, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.17.562693 · Cited by 1
“As a result, despite wide-recognized roles of R2HG in cancer development 49, 50 , there is no proteome-wide investigation of R2HG binding proteins.”
BackgroundSelf-citationWang, Z., Du, X., Zhang, P., Zhao, M., Zhang, T., Liu, J., Wang, X., Chang, D., Liu, X., Bian, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4435634/v1 · Cited by 1
Fto Facilitates Colorectal Cancer Chemoresistance Via Regulation of Nupr1-Dependent Iron HomeostasisPreprint
Xu, C., Shen, L., Shen, T., Feng, L., Li, S., Ding, R., Fan, M., Wang, W., Zheng, J., & Qu, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5011028 · Cited by 1
Huang, F., Luo, X., Zhang, M., Jin, L., Sun, W., Chen, P., Hong, X., Xu, C., Jiang, M., Hu, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.15.643466 · Cited by 1
Self-citationThe promoter becomes the suppressor
Seton-Rogers, S. E. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2018.8
The Role of mRNA m6A in Regulation of Gene Expression
Zhang, S. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_14
N6-methyladenosine-modifying enzymes are deregulated in multiple myeloma
Yildiz, D. A. (2020) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.489326
Elf, S. E., & Chen, J. (2021) · Blood Science · doi:10.1097/bs9.0000000000000067
“This group previously screened 27 IDH1/2-wild type AML cell lines for their growth sensitivity to R-2-HG.(14) Here, they have”
BackgroundMethodInfluentialSelf-citationCrosstalk between Fat Mass and Obesity-related (FTO) and multiple WNT signaling pathwaysPreprint
Kim, H., Jang, S., & Lee, Y.-S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.20.444911
Role of m6A methylation in occurrence and progression of digestive system malignancies
Liang, R.-H., Zhu, N.-X., Hou, Q., & Wu, L. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i14.747
Morón-Calvente, V., & Blanco, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00255-z
Liu, J.-Y., Li, B., Xu, E., & Zhong, Y. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i23.1373
Jiao, Y., Shi, H., Fu, C., Quan, P., & Zhang, L. Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1408109/v1
Shi, H., Fu, C., Quan, P., Zhang, L., Liu, Y., & Jiao, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1408109/v2
Expression Status and Prognostic Value of m6A RNA Methylation Regulators in Lung AdenocarcinomaPreprint
Wang, R., Feng, Z., Hu, J., He, X., & Shen, Z. (2020) · Research Square · doi:10.21203/rs.3.rs-120253/v1
Biochemical and Genetic Markers in Neurological Trauma and Tumors: Review Article
Ashraf, O., Saleem, T. H., Elsadek, B., Hamdan, A. R. K., & Hassan, M. H. (2022) · Asian Journal of Biochemistry Genetics and Molecular Biology · doi:10.9734/ajbgmb/2022/v11i230260
TSE, C. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60060
Progress in Molecular Mechanism of RNA N6-Methyladenosine Modification in Breast Cancer
郑, 仁. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125555
m6A Demethylase FTO regulates nasopharyngeal carcinoma invasion, migrationPreprint
Liao, Z., Ye, F., Tao, Y., Wang, J., Huang, G., Yang, S., Lu, Z., Zhu, H., & Wu, P. (2022) · Research Square · doi:10.21203/rs.3.rs-2004749/v1
Molecular Biology, Genetics, and Translational Models of Human Cancer
Traub, B., Scheufele, F., Viswanathan, S. R., Meyerson, M. M., & Tuveson, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm003.pub2
Maimaiti, A., Baihetiyaer, Y., Turhon, M., Abulaiti, A., Cui, X., Pei, Y., Aili, Y., Aerken, D., Jiang, L., Wang, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2371294/v1
Self-citationEpi-Drugs Targeting RNA Dynamics in Cancer
Bove, G., Lettiero, I., Sgueglia, G., Gaudio, N. D., Altucci, L., & Dell’Aversana, C. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_113
Regulation of posttranscriptional events by RNA-binding proteins
Kumar, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99521-4.00017-9
Sagaityte, E., Dowd, R. S., Lane, K., Graff, S. L., & Toms, S. A. (2023) · Advances in Breast Cancer Research · doi:10.4236/abcr.2023.122004
Xu, S., Wang, M., Xu, J., & Wu, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3362761/v1
Rabiei, M., Attar, S. M. G., Ghalandarpoor‐Attar, S. N., & Nurzadeh, M. (2023) · Human Gene · doi:10.1016/j.humgen.2023.201232
Multifaceted Functions of RNA m6A Modification in Modulating Regulated Cell Death
Zhan, G., Liu, J., Lin, J., Chen, J., Sun, S., Maimaitiyiming, Y., & Hsu, C.-H. (2023) · RNA technologies · doi:10.1007/978-3-031-36390-0_24
Self-citationRole of Myc in Brain Tumor Development
Shahi, M. H. (2023) · Springer eBooks · doi:10.1007/978-981-15-8473-2_10
RNA Modifications in Hematologic Malignancies
Li, Y., Tian, W., & Zhang, H. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_6
Adam, J., Harada, M., Covic, M., Brandmaier, S., Muschet, C., Huang, J., Han, S., Ge, J., Rommel, M., Rotter, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3931333/v1
Tuhongjiang, A., Wang, F., Zhang, C.-R., Pang, S., Qu, Y., Feng, B., & Amuti, G. (2023) · Figshare · doi:10.6084/m9.figshare.22639623
Chen, B., Yang, Z., Lang, Z., Tao, Q., Zhang, R., Zhan, Y., Xu, X., Zhu, K., Zheng, J., Yu, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20455451
Xu, P., Hu, K., Zhang, P., Sun, Z., & Zhang, N. (2022) · Figshare · doi:10.6084/m9.figshare.18070522
Chai, R., Chang, Y., Chang, X., Pang, B., An, S. Y., Zhang, K., Chang, Y., Jiang, T., & Wang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14954712
Self-citationTuhongjiang, A., Wang, F., Zhang, C.-R., Pang, S., Qu, Y., Feng, B., & Amuti, G. (2023) · Figshare · doi:10.6084/m9.figshare.22639626
Chen, Y., Lu, Z., Qi, C., Yu, C., Li, Y., Wang, H., Wang, R., Luo, W., Shen, D., Ding, L., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19745056
Xu, F., Li, J., Ni, M., Cheng, J., Zhao, H., Wang, S., Zhou, X. Y., & Wu, X. (2021) · Figshare · doi:10.6084/m9.figshare.14157853
Tuhongjiang, A., Wang, F., Zhang, C.-R., Pang, S., Qu, Y., Feng, B., & Amuti, G. (2023) · Figshare · doi:10.6084/m9.figshare.22639638
Xu, P., Hu, K., Zhang, P., Sun, Z., & Zhang, N. (2022) · Figshare · doi:10.6084/m9.figshare.18070519
Xu, P., Hu, K., Zhang, P., Sun, Z., & Zhang, N. (2022) · Figshare · doi:10.6084/m9.figshare.18070525
Chen, B., Yang, Z., Lang, Z., Tao, Q., Zhang, R., Zhan, Y., Xu, X., Zhu, K., Zheng, J., Yu, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20455466
Metadata
- Authors
- Su, R., Dong, L., Li, C., Nachtergaele, S., Wunderlich, M., Qing, Y., Deng, X., Wang, Y., Weng, X., Hu, C., Yu, M., Skibbe, J., Dai, Q., Zou, D., Wu, T., Yu, K., Weng, H., Huang, H., Ferchen, K., Qin, X., Zhang, B., Qi, J., Sasaki, A. T., Plas, D. R., Bradner, J. E., Wei, M., Marcucci, G., Jiang, X., Mulloy, J. C., Jin, J., He, C., & Chen, J.
- Affiliations
- University of Cincinnati (US)
- First Affiliated Hospital Zhejiang University (CN)
- Howard Hughes Medical Institute (US)
- Cincinnati Children's Hospital Medical Center (US)
- Chongqing Cancer Hospital (CN)
- City Of Hope National Medical Center (US)
- Harvard University (US)
- China Medical University (CN)
- Corresponding author
- Jin, Jie
- He, Chuan
- Chen, Jianjun
- ORCID
- Su, Rui
- Dong, Lei
- Li, Chenying
- Nachtergaele, Sigrid
- Wunderlich, Mark
- Qing, Ying
- Deng, Xiaolan
- Weng, Xiaocheng
- Hu, Chao
- Yu, Mengxia
- Skibbe, Jennifer
- Dai, Qing
- Zou, Dongling
- Wu, Tong
- Weng, Hengyou
- Huang, Huilin
- Ferchen, Kyle
- Qin, Xi
- Zhang, Bin
- Qi, Jun
- Sasaki, Atsuo T.
- Plas, David R.
- Bradner, James E.
- Wei, Minjie
- Marcucci, Guido
- Jiang, Xi
- Mulloy, James C.
- Jin, Jie
- He, Chuan
- Chen, Jianjun
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 172
- Issue
- 1-2
- Pages
- 90-105.e23
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5766423
- OpenAlex
- W2772792536
- Cited by
- 1,137
- References
- 43
- Citations by year
- 2026: 75 · 2025: 100 · 2024: 161 · 2023: 163 · 2022: 165 · 2021: 197 · 2020: 150 · 2019: 76 · 2018: 48
- FWCI
- 31.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (CA214965, CA211614, CA178454, CA182528, RM1 HG008935, GM071440, R50 CA211404, R01NS089815, R21NS100077)
- Foundation of Innovation Team for Basic and Clinical Research of Zhejiang Province (2011R50015)
- Academic and Research Committee of Cincinnati Children’s Hospital Medical Center
- Leukemia & Lymphoma Society
- Howard Hughes Medical Institute
- Damon Runyon Cancer Research Foundation (DRG-2215-15)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- (R)-2-hydroxyglutarate, 2-hydroxyglutarate, FTO, N6-methyladenosine modification, c-Myc, CEBPA, leukemia, glioma, IDH1/2 mutation, oncometabolites, RNA stability, cell cycle arrest, apoptosis
- MeSH terms
- Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Adenosine, Animals, Antineoplastic Agents, Brain Neoplasms, Glioma, Glutarates, Humans, Leukemia, RNA Processing, Post-Transcriptional, Signal Transduction, Proto-Oncogene Proteins c-myc, Jurkat Cells, CCAAT-Enhancer-Binding Proteins, Cell Line, Tumor, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
